Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Catalyst Pharmaceuticals Inc is a biotechnology business based in the US. Catalyst Pharmaceuticals shares (CPRX) are listed on the NASDAQ and all prices are listed in US Dollars. Catalyst Pharmaceuticals employs 76 staff and has a trailing 12-month revenue of around $170.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $12.70 |
|---|---|
| 52-week range | $5.04 - $17.22 |
| 50-day moving average | $12.60 |
| 200-day moving average | $8.55 |
| Wall St. target price | $16.90 |
| PE ratio | 24.18 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.50 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.7 from 2022-09-29
| 1 week (2022-09-23) | 6.99% |
|---|---|
| 1 month (2022-09-01) | -9.16% |
| 3 months (2022-07-01) | 79.89% |
| 6 months (2022-04-01) | 52.46% |
| 1 year (2021-10-01) | 143.76% |
|---|---|
| 2 years (2020-10-01) | 305.75% |
| 3 years (2019-10-01) | 154.00% |
| 5 years (2017-09-29) | 403.97% |
Valuing Catalyst Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Catalyst Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Catalyst Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Catalyst Pharmaceuticals shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Catalyst Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $72.8 million.
The EBITDA is a measure of a Catalyst Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $170.5 million |
|---|---|
| Operating margin TTM | 42.64% |
| Gross profit TTM | $102 million |
| Return on assets TTM | 19.07% |
| Return on equity TTM | 25.35% |
| Profit margin | 31.97% |
| Book value | $2.35 |
| Market capitalisation | $1.2 billion |
TTM: trailing 12 months
We're not expecting Catalyst Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Catalyst Pharmaceuticals's shares have ranged in value from as little as $5.04 up to $17.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catalyst Pharmaceuticals's is 1.3116. This would suggest that Catalyst Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Catalyst Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc. ; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
